VIGAFYDE Drug Patent Profile
✉ Email this page to a colleague
When do Vigafyde patents expire, and when can generic versions of Vigafyde launch?
Vigafyde is a drug marketed by Pyros Pharms and is included in one NDA. There is one patent protecting this drug.
This drug has three patent family members in two countries.
The generic ingredient in VIGAFYDE is vigabatrin. There are five drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the vigabatrin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Vigafyde
A generic version of VIGAFYDE was approved as vigabatrin by ENDO OPERATIONS on April 27th, 2017.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for VIGAFYDE?
- What are the global sales for VIGAFYDE?
- What is Average Wholesale Price for VIGAFYDE?
Summary for VIGAFYDE
| International Patents: | 3 |
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| What excipients (inactive ingredients) are in VIGAFYDE? | VIGAFYDE excipients list |
| DailyMed Link: | VIGAFYDE at DailyMed |
Pharmacology for VIGAFYDE
| Drug Class | Anti-epileptic Agent |
US Patents and Regulatory Information for VIGAFYDE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pyros Pharms | VIGAFYDE | vigabatrin | SOLUTION;ORAL | 217684-001 | Jun 17, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for VIGAFYDE
See the table below for patents covering VIGAFYDE around the world.
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
